Two mifepristone manufacturers have petitioned the Supreme Court to halt a recent ruling by the U.S. Court of Appeals for the 5th Circuit, which reinstated an in-person dispensing requirement for the abortion pill. This development is critical as it could disrupt access to medication abortions, affecting healthcare providers and patients reliant on current telehealth and mail-order protocols. The Supreme Court's decision will determine whether the drug remains widely accessible or if stricter regulations are enforced.
Read the full article at SCOTUSblog
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
2
Ali NematiWritten by Ali
![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)
